Staging of Alzheimer’s disease: past, present, and future perspectives

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

(2022) Nicholas J. Ashton et al.   EBioMedicine

Subtypes of Alzheimer’s disease: questions, controversy, and meaning

(2022) Jacob W. Vogel et al.   TRENDS IN NEUROSCIENCES

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease

(2022) Christina B. Young et al.   JAMA Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Reactive astrocyte nomenclature, definitions, and future directions

(2021) Carole Escartin et al.   NATURE NEUROSCIENCE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain

(2021) Amit Kumar et al.   MOLECULAR PSYCHIATRY

Four distinct trajectories of tau deposition identified in Alzheimer’s disease

(2021) Jacob W. Vogel et al.   NATURE MEDICINE

Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis

(2021) Bruna Bellaver et al.   NEUROLOGY

Progress with Treatments for Alzheimer’s Disease

(2021) Allan I. Levey   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages

(2021) Tharick A Pascoal et al.   BRAIN

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

(2021) Rik Ossenkoppele et al.   EMBO Molecular Medicine

Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load

(2021) Valeria Calsolaro et al.   MOLECULAR PSYCHIATRY

Microglial activation and tau propagate jointly across Braak stages

(2021) Tharick A. Pascoal et al.   NATURE MEDICINE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Developing the ATX(N) classification for use across the Alzheimer disease continuum

(2021) Harald Hampel et al.   Nature Reviews Neurology

Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays

(2021) Antoine Leuzy et al.   NEUROLOGY

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

(2021) Juan Lantero‐Rodriguez et al.   EMBO Molecular Medicine

Microglia contribute to the propagation of Aβ into unaffected brain tissue

(2021) Paolo d’Errico et al.   NATURE NEUROSCIENCE

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

(2021) Andréa L. Benedet et al.   JAMA Neurology

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia

(2021) Joseph Therriault et al.   Annals of Clinical and Translational Neurology

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Amyloid‐β oligomers in cellular models of Alzheimer’s disease

(2020) Igor C. Fontana et al.   JOURNAL OF NEUROCHEMISTRY

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

(2020) Nicholas J. Ashton et al.   Nature Reviews Neurology

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease

(2020) Eduard Vilaplana et al.   NEUROLOGY

Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

(2020) Jacob W. Vogel et al.   Nature Communications

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

(2020) Reisa A. Sperling et al.   JAMA Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

18F-SMBT-1: A Selective and Reversible Positron-Emission Tomography Tracer for Monoamine Oxidase-B Imaging

(2020) Ryuichi Harada et al.   JOURNAL OF NUCLEAR MEDICINE

Determining Amyloid-β positivity using [18F]AZD4694 PET imaging

(2020) Joseph Therriault et al.   JOURNAL OF NUCLEAR MEDICINE

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Multi-tracer model for staging cortical amyloid deposition using PET imaging

(2020) Lyduine E. Collij et al.   NEUROLOGY

Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs

(2020) Serge Gauthier et al.   Expert Review of Neurotherapeutics

Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease

(2020) Ilaria Vanzulli et al.   NEUROBIOLOGY OF AGING

Topographical distribution of amyloid-β, tau and atrophy in behavioral / dysexecutive AD patients

(2020) Joseph Therriault et al.   NEUROLOGY

Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease

(2020) Joseph W. Lewcock et al.   NEURON

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

(2020) Angela Tian Hui Kwan et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life

(2020) Ruth E. Uhlmann et al.   NATURE NEUROSCIENCE

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease

(2020) Oskar Hansson et al.   Annals of Clinical and Translational Neurology

Myelin quantification with MRI: A systematic review of accuracy and reproducibility

(2020) Chris W.J. van der Weijden et al.   NEUROIMAGE

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

(2019) Marc Suárez-Calvet et al.   Molecular Neurodegeneration

Astrocyte Biomarkers in Alzheimer’s Disease

(2019) Stephen F. Carter et al.   TRENDS IN MOLECULAR MEDICINE

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease

(2019) John C. Morris et al.   JAMA Neurology

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

(2019) Peter T Nelson et al.   BRAIN

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The astrocyte biochemistry

(2019) Débora G. Souza et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia

(2019) Clifford R. Jack et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Parkinson’s disease biomarkers based on α‐synuclein

(2019) Muneera Fayyad et al.   JOURNAL OF NEUROCHEMISTRY

α-synuclein in the pathophysiology of Alzheimer’s disease

(2019) Daniel Twohig et al.   Molecular Neurodegeneration

Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework

(2019) Clifford R. Jack et al.   JAMA Neurology

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography

(2019) Niklas Mattsson et al.   JAMA Neurology

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

(2019) Clifford R Jack et al.   BRAIN

Microglia Biology: One Century of Evolving Concepts

(2019) Marco Prinz et al.   CELL

The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging

(2019) Enrico Fantoni et al.   JOURNAL OF NUCLEAR MEDICINE

To stage, or not to stage

(2019) Kelly Del Tredici et al.   CURRENT OPINION IN NEUROBIOLOGY

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Combined neuropathological pathways account for age-related risk of dementia

(2018) Melinda C. Power et al.   ANNALS OF NEUROLOGY

A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment

(2018) Hua Wang et al.   JOURNAL OF ALZHEIMERS DISEASE

Evaluation of11C-BU99008, a positron emission tomography ligand for the Imidazoline2binding site in human brain

(2018) Robin J. Tyacke et al.   JOURNAL OF NUCLEAR MEDICINE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals

(2018) Heidi I. L. Jacobs et al.   NATURE NEUROSCIENCE

Subjective cognitive decline and risk of MCI

(2018) Argonde C. van Harten et al.   NEUROLOGY

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease

(2018) Frederic Brosseron et al.   Alzheimers Research & Therapy

α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

(2018) Ane Korff et al.   JOURNAL OF ALZHEIMERS DISEASE

Imaging the evolution and pathophysiology of Alzheimer disease

(2018) William Jagust   NATURE REVIEWS NEUROSCIENCE

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease

(2018) Stephen F. Carter et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer’s Disease

(2017) Stephanie M. Williams et al.   JOURNAL OF ALZHEIMERS DISEASE

Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia

(2017) K Chiotis et al.   MOLECULAR PSYCHIATRY

Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis

(2017) Paolo Eusebi et al.   MOVEMENT DISORDERS

Neurotoxic reactive astrocytes are induced by activated microglia

(2017) Shane A. Liddelow et al.   NATURE

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

(2017) Chenjie Xia et al.   JAMA Neurology

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

(2016) Laura Piccio et al.   ACTA NEUROPATHOLOGICA

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

(2016) Amanda Heslegrave et al.   Molecular Neurodegeneration

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease

(2016) Keun-A Chang et al.   NEUROCHEMISTRY INTERNATIONAL

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies

(2016) Graham Fairfoul et al.   Annals of Clinical and Translational Neurology

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Regional brain hypometabolism is unrelated to regional amyloid plaque burden

(2015) Andre Altmann et al.   BRAIN

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

(2015) Richard A. Insel et al.   DIABETES CARE

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies

(2015) Joery Goossens et al.   Acta Neuropathologica Communications

Primary age-related tauopathy (PART): a common pathology associated with human aging

(2014) John F. Crary et al.   ACTA NEUROPATHOLOGICA

TDP-43 is a key player in the clinical features associated with Alzheimer’s disease

(2014) Keith A. Josephs et al.   ACTA NEUROPATHOLOGICA

Self-reported memory complaints: Implications from a longitudinal cohort with autopsies

(2014) R. J. Kryscio et al.   NEUROLOGY

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age

(2013) Robert S. Wilson et al.   JAMA Neurology

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG

(2012) S. F. Carter et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

TAR DNA-binding protein 43 in neurodegenerative disease

(2010) Alice S. Chen-Plotkin et al.   Nature Reviews Neurology

Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease

(2010) Min Shi et al.   NEUROSCIENCE LETTERS

The neuropathology of probable Alzheimer disease and mild cognitive impairment

(2009) Julie A. Schneider et al.   ANNALS OF NEUROLOGY

TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration

(2008) Penelope Foulds et al.   ACTA NEUROPATHOLOGICA

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

(2008) Robin Barbour et al.   Neurodegenerative Diseases

Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype

(2008) K. A. Josephs et al.   NEUROLOGY